Free Trial

DaVita (DVA) Stock Forecast & Price Target

DaVita logo
$151.85 +4.31 (+2.92%)
(As of 12/20/2024 05:45 PM ET)

DaVita - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
3
Buy
1

Based on 5 Wall Street analysts who have issued ratings for DaVita in the last 12 months, the stock has a consensus rating of "Hold." Out of the 5 analysts, 1 has given a sell rating, 3 have given a hold rating, and 1 has given a buy rating for DVA.

Consensus Price Target

$161.80
6.55% Upside
According to the 5 analysts' twelve-month price targets for DaVita, the average price target is $161.80. The highest price target for DVA is $175.00, while the lowest price target for DVA is $145.00. The average price target represents a forecasted upside of 6.55% from the current price of $151.85.
Get the Latest News and Ratings for DVA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for DaVita and its competitors.

Sign Up

DVA Analyst Ratings Over Time

TypeCurrent Forecast
12/22/23 to 12/21/24
1 Month Ago
11/22/23 to 11/21/24
3 Months Ago
9/23/23 to 9/22/24
1 Year Ago
12/22/22 to 12/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
2 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$161.80$161.80$157.00$102.67
Forecasted Upside6.55% Upside-1.50% Downside-4.27% Downside-1.59% Downside
Consensus Rating
Hold
Hold
Hold
Moderate Buy

DVA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

DVA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

DaVita Stock vs. The Competition

TypeDaVitaMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.81
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside6.55% Upside25,828.93% Upside14.53% Upside
News Sentiment Rating
Positive News

See Recent DVA News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/31/2024Barclays
3 of 5 stars
 Boost TargetEqual Weight ➝ Equal Weight$150.00 ➝ $164.00+16.89%
10/7/2024Truist Financial
2 of 5 stars
 Boost TargetHold ➝ Hold$165.00 ➝ $175.00+8.91%
8/8/2024UBS Group
4 of 5 stars
 Boost TargetBuy ➝ Buy$169.00 ➝ $175.00+27.88%
8/7/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetUnderperform ➝ Underperform$139.00 ➝ $145.00+9.55%
7/24/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$139.00 ➝ $150.00+5.31%
5/15/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$88.00 ➝ $100.00+6.70%
5/9/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$85.00 ➝ $113.00+10.50%
2/23/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$76.00 ➝ $90.00+5.42%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 12:16 PM ET.


DVA Forecast - Frequently Asked Questions

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for DaVita is $161.80, with a high forecast of $175.00 and a low forecast of $145.00.

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DaVita in the last twelve months. There is currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DVA, but not buy additional shares or sell existing shares.

According to analysts, DaVita's stock has a predicted upside of 6.55% based on their 12-month stock forecasts.

DaVita has been rated by research analysts at Barclays, and Truist Financial in the past 90 days.

Analysts like DaVita less than other "medical" companies. The consensus rating for DaVita is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how DVA compares to other companies.


This page (NYSE:DVA) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners